22162-19-2

Basic information

• Product Name: (4-nitro-1,2-phenylene)diMethanol
• Synonyms: (4-nitro-1,2-phenylene)diMethanol
• CAS NO: 22162-19-2
• Molecular Formula: C₈H₉NO₄
• Molecular Weight: 183.16136
• Mol File: 22162-19-2.mol
• Article Data: 32

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (4-nitro-1,2-phenylene)diMethanol(CAS DataBase Reference)
• NIST Chemistry Reference: (4-nitro-1,2-phenylene)diMethanol(22162-19-2)
• EPA Substance Registry System: (4-nitro-1,2-phenylene)diMethanol(22162-19-2)

Safety Data

• Hazardous Substances Data: 22162-19-2(Hazardous Substances Data)

Usage

General Description

(4-nitro-1,2-phenylene)dimethanol, also known as NDPM, is a chemical compound with the formula C8H9NO5. It is a nitro-substituted diol that is used in the manufacture of various products including pigments, dyes, and pharmaceuticals. NDPM is a yellow crystalline solid that is sparingly soluble in water and has a high melting point. It is primarily used as an intermediate in the synthesis of other chemicals and materials, and it is important to handle it with care due to its potential health and environmental hazards. Overall, NDPM is a versatile compound with important industrial applications.

Upstream product

• 6425-66-7 1,2-bis-bromomethyl-4-nitro-benzene 
• 5466-84-2 4-nitrophthalic anhydride 
• 610-27-5 4-nitrophthalic acid 
• 610-93-5 6-nitrophthalide 
• 99-51-4 4-nitro-o-xylene 
• 2050-19-3 4-nitrophthalic acid diethyl ester 

Downstream Products

• 6425-66-7 1,2-bis-bromomethyl-4-nitro-benzene 
• 13209-35-3 4-nitrobenzene-1,2-dicarbaldehyde 
• 346419-79-2 6-aminophthalazine 
• 1189570-37-3 (2R)-5-({2-[(8R)-8-(3-difluorophenyl)-8-methyl-10-oxo-6,9-diazaspiro[4,5]dec-9-yl]ethyl}sulfanyl)-1'-{[2-(trimethylsiryl)ethoxy]methyl}-1,3-dihydrospiro[indene-2,3'-pyrrolo[2,3-b]pyridin]-2'(1'H)-one 
• 1189569-41-2 (2S)-6-{(1E)-3-[(8R)-8-(3,5-difluorophenyl)-8-methyl-10-oxo-6,9-diazaspiro[4,5]dec-9-yl]prop-1-en-1-yl}-2'-oxo-1,1',2',3-tetrahydrospiro[indene-2,3'-pyrrolo[2,3-b]pyridine]-5-carbonitrile 
• 1189569-38-7 (2R)-5-({2-[(8R)-8-(3,5-difluorophenyl)-8-methyl-10-oxo-6,9-diazaspiro[4,5]dec-9-yl]ethyl}sulfinyl)-1,3-dihydrospiro[indene-2,3'-pyrrolo[2,3-b]pyridin]-2'(1'H)-one 
• 1189569-08-1 (2R)-5-{3-[(8R)-8-(3,5-difluorophenyl)-8-methyl-10-oxo-6,9-diazaspiro[4,5]dec-9-yl]prop-1-yn-1-yl}-1,3-dihydrospiro[indene-2,3'-pyrrolo[2,3-b]pyridin]-2'(1'H)-one 
• 1189569-37-6 (2R)-5-({2-[(8R)-8-(3,5-difluorophenyl)-8-methyl-10-oxo-6,9-diazaspiro[4,5]dec-9-yl]ethyl}sulfanyl)-1,3-dihydrospiro[indene-2,3'-pyrrolo[2,3-b]pyridin]-2'(1'H)-one 
• 1189569-34-3 (2R)-5-{(1E)-3-[2-(3,5-difluorophenyl)-5-(fluoromethyl)-2,4,5-trimethyl-6-oxopiperazin-1-yl]prop-1-en-1-yl}-1,3-dihydrospiro[indene-2,3'-pyrrolo[2,3-b]pyridin]-2'(1'H)-one 
• 1189569-40-1 (2R)-5-{(1E)-3-[(7R,9aR)-7-(3,5-difluorophenyl)-9-oxohexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-yl]prop-1-en-1-yl}-1,3-dihydrospiro[indene-2,3 '-pyrrolo[2,3-b]pyridin]-2'(1'H)-one 5 
• 1059185-34-0 2-[5-(3,5-difluorophenyl)-3-ethyl-5-methyl-2,4-dioxoimidazolidin-1-yl]-N-[(2R)-2'-oxo-1,1',2',3-tetrahydrospiro[indene-2,3'-pyrrolo[2,3-b]pyridin]-5-yl]acetamide 
• 1033608-31-9 tert-butyl (+/-)-(2'-oxo-1'-{[2-(trimethylsilyl)ethoxy]methyl}-1,1',2',3-tetrahydrospiro[indene-2,3'-pyrrolo[2,3-b]pyridin]-5-yl)carbamate 
• 957121-34-5 tert-butyl (R)-(2'-oxo-1'-{[2-(trimethylsilyl)ethoxy]methyl}-1,1',2',3-tetrahydrospiro[indene-2,3'-pyrrolo[2,3-b]pyridin]-5-yl)carbamate 
• 957121-35-6 tert-butyl (S)-(2'-oxo-1'-{[2-(trimethylsilyl)ethoxy]methyl}-1,1',2',3-tetrahydrospiro[indene-2,3'-pyrrolo[2,3-b]pyridin]-5-yl)carbamate 

Relevant articles and documents

The discovery of highly potent CGRP receptor antagonists

Rational modification of a previously identified spirohydantoin lead structure has identified a series of potent spiroazaoxindole CGRP receptor antagonists. The azaoxindole was found to be a general replacement for the hydantoin that consistently improved

HETEROCYCLIC SPIRO-COMPOUNDS AS AM2 RECEPTOR INHIBITORS

Disclosed are compounds of the formula (I) and pharmaceutically acceptable salts thereof: wherein HET, R1, R2, R3, R4, R5, L, L1, X1, X2, X3 and q are as defined herein. The compounds are inhibitors of adrenomedullin receptor subtype 2 (AM2). Also disclosed are the compounds for use in the treatment of diseases modulated AM2, including proliferative diseases such as cancer; pharmaceutical compositions comprising the compounds; methods for preparing the compounds; and intermediates useful in the preparation of the compounds.

FlICk (fluorescent isoindole crosslinking) for peptide stapling

The rigidification of peptide secondary structure via stapling is an important and enduring goal in the development of functional peptides for biochemical and pharmaceutical applications. In addition, the incorporation of fluorophores and chromophores has